Canadian Cancer Trials Group Senior Investigator Dr. Carlos Paiva is a medical oncologist and Associate Professor in the Department of Oncology at Queen’s University. He serves as a Senior Investigator at the Canadian Cancer Trials Group (CCTG), contributing to the Breast, Gynecologic, and Supportive Care Committees.Prior to joining Queen’s University, Dr. Paiva held academic leadership roles in Brazil, where he coordinated a graduate oncology program and led clinical research initiatives with a particular emphasis on supportive care and patient-centered outcomes in breast and gynecologic cancers. His work aims to optimize treatment strategies, reduce treatment burden, and improve quality of life for patients. He serves as a scientific reviewer for multiple peer-reviewed journals and is currently Section Editor of Cancer Control.Areas of expertise: Clinical Trials, Breast, Gynecologic, Supportive CareResearch interests: Breast Cancer, Supportive Care, De-escalation Trials, Goals of Care and Shared Decision-Making Selected Publications:Lorusso D, Oaknin A, Borges GS, Damian F, Ottevanger N, Van Gorp T, Paiva CE, Kroep JR, Kim YM, Kim HS, Lee JK, Denys H, Lalisang R, De Melo AC, Redondo A, Reyners AKL, Mora P, Closset C, Melief CJM, Hooftman L, Jamil S, Boersma L, Yoo SY, Seebach F, Lowy I, Fury MG, Mathias M, Colombo N. Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial. Gynecol Oncol. 2025 May;196:28-35. doi: 10.1016/j.ygyno.2025.03.019. Epub 2025 Mar 27. PMID: 40154184. Paiva CE, Preto DD, de Lima C, Paiva BSR. To Treat or Not to Treat? Dilemmas when Deciding on Antineoplastic Treatment in Patients With Far Advanced Cancers. Cancer Control. 2023 Jan-Dec;30:10732748231176639. doi: 10.1177/10732748231176639. PMID: 37178323; PMCID: PMC10184254. de Pádua Souza C, Carneiro ASB, de Oliveira Lessa AC, Lacerda DC, Paiva CE, Zorzetto MMC, de Freitas AJA, Santana IVV, de Oliveira MA, Palmero EI, Marques MMC, Reinert T. Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial. Breast Cancer Res Treat. 2023 Nov;202(1):57-65. doi: 10.1007/s10549-023-07011-0. Epub 2023 Aug 14. PMID: 37578666; PMCID: PMC10504209. Paiva CE, Paiva BSR, de Paula Pântano N, Preto DD, de Oliveira CZ, Yennurajalingam S, Hui D, Bruera E. Development and validation of a prognostic nomogram for ambulatory patients with advanced cancer. Cancer Med. 2018 Jul;7(7):3003-3010. doi: 10.1002/cam4.1582. Epub 2018 Jun 1. PMID: 29856126; PMCID: PMC6051167. Hui D, Shamieh O, Paiva CE, Perez-Cruz PE, Kwon JH, Muckaden MA, Park M, Yennu S, Kang JH, Bruera E. Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study. Cancer. 2015 Sep 1;121(17):3027-35. doi: 10.1002/cncr.29437. Epub 2015 Jun 8. PMID: 26059846; PMCID: PMC4595042. de Oliveira Rodrigues DD, Ribeiro Paiva BS, Lacerda DC, Serrano SV, Morelle AM, Barrios C, Rocha MS, Casanova Schulze PA, Paiva CE. Feasibility and Implementation of a Digital Health Intervention Electronic Patient-Reported Outcomes-Based Platform for Telemonitoring Patients With Breast Cancer Undergoing Chemotherapy. JCO Clin Cancer Inform. 2025 Aug;9:e2500018. doi: 10.1200/CCI-25-00018. Epub 2025 Aug 13. PMID: 40802911. For a full list of publications please visit https://pubmed.ncbi.nlm.nih.gov/?term=paiva%20ce%20%5Bau%5D
